


# Data Sheet

Global Supplier of Chemical Probes, Inhibitors &amp; Agonists.

---

<b>Product Name</b>	: Lenalidomide
<b>Cat. No.</b>	: PC-20467
<b>CAS No.</b>	: 191732-72-6
<b>Molecular Formula</b>	: C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight</b>	: 259.27
<b>Target</b>	: E3 Ligase Ligand
<b>Solubility</b>	: 10 mM in DMSO



## Biological Activity

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue for **PROTAC** design, Lenalidomide is a ligand of **ubiquitin E3 ligase cereblon (CRBN)**, and causes selective ubiquitination and degradation of IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.

Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

Lenalidomide (CC-5013) inhibits production of pro inflammatory cytokines TNF- $\alpha$ , IL-1, IL-6, IL-12 and elevates the production of anti-inflammatory cytokine IL-10 from human PBMCs.

Lenalidomide (CC-5013) downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction.

Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay.

## References

- Krönke J, et al. **Oncoimmunology**. 2014 Jul 3;3(7):e941742.  
Kotla V, et al. **J Hematol Oncol**. 2009 Aug 12;2:36.  
Lopez-Girona A, et al. **Leukemia**. 2012 Nov;26(11):2326-35.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---